Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909289 | 1.00 | ABCG2 (0.51) | ABCG2DHODHPDE5AALDH1A1MAPK1 | |
| SCHEMBL23577419 | 0.93 | ABCG2 (0.52) | ABCG2PDE5AHCRTR1SMN1; SMN2 | |
| SCHEMBL31229721 | 0.93 | ABCG2 (0.52) | ABCG2PDE5AHCRTR1SMN1; SMN2 | |
| SCHEMBL29909029 | 0.93 | ABCG2 (0.45) | ABCG2DHODHPDE5AALDH1A1MAPK1 | |
| SCHEMBL23576621 | 0.93 | ABCG2 (0.45) | ABCG2DHODHPDE5AALDH1A1MAPK1 | |
| SCHEMBL23578033 | 0.91 | PDE5A (0.44) | ABCG2DHODHPDE5AALDH1A1MAPK1 | |
| SCHEMBL29909329 | 0.88 | ABCG2 (0.47) | ABCG2DHODHPDE5AALDH1A1KDM4E | |
| SCHEMBL23577176 | 0.88 | ABCG2 (0.47) | ABCG2DHODHPDE5AALDH1A1KDM4E | |
| SCHEMBL23576805 | 0.87 | ABCG2 (0.42) | ABCG2DHODHPDE5AALDH1A1MAPK1 | |
| SCHEMBL29909532 | 0.87 | ABCG2 (0.42) | ABCG2DHODHPDE5AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ABCG2 4216/4885DHODH 1705/4885PDE5A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.